Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed B-cell chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) arising from CLL~  * No de novo PLL~ * Lymphocyte count \> 5,000/mm\^3 at some point since initial diagnosis of CLL~ * B-cells co-expressing CD5 AND CD19 or CD20~ * If no dim serum immunoglobulin or CD23 expression on leukemia cells, must be examined for cyclin D1 overexpression OR t(11;14) to rule out mantle cell lymphoma~* Requiring therapy, defined by any of the following:~  * Massive or progressive splenomegaly and/or lymphadenopathy~ * Anemia (hemoglobin \< 11 g/dL) OR thrombocytopenia (platelet count \< 100,000/mm\^3)~ * Weight loss \> 10% within the past 6 months~ * Grade 2 or 3 fatigue~ * Fevers \> 100.5°C or night sweats for \> 2 weeks with no evidence of infection~ * Progressive lymphocytosis with an increase of \> 50% over a 2-month period OR an anticipated doubling time \< 6 months~* Received ≥ 1 prior chemotherapy regimen that included fludarabine or nucleoside equivalent OR alternative therapy if contraindication to fludarabine exists (i.e., autoimmune hemolytic anemia)~* Performance status - ECOG 0-2~* More than 2 years~* See Disease Characteristics~* Baseline cytopenias allowed~* WBC ≤ 200,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Gilbert's disease, hemolysis, or disease infiltration of the liver)~* AST ≤ 2 times ULN (unless due to hemolysis or disease infiltration of the liver)~* Creatinine ≤ 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy that would limit life expectancy~* See Disease Characteristics~* No other concurrent chemotherapy~* No concurrent chronic corticosteroids or corticosteroids as antiemetics~* No concurrent hormonal therapy except steroids for new adrenal failure or hormones for nondisease-related conditions (e.g., insulin for diabetes)~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (alvocidib) (Type: EXPERIMENTAL): Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for \> 6 months after completion of treatment may receive 6 additional courses of flavopiridol.

Based on this trial design, predict the completion outcome and termination type (if applicable).